Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Grows By 42.4%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 1,459,615 shares, an increase of 42.4% from the November 30th total of 1,025,313 shares. Currently, 3.9% of the shares of the stock are short sold. Based on an average daily volume of 476,178 shares, the short-interest ratio is presently 3.1 days. Based on an average daily volume of 476,178 shares, the short-interest ratio is presently 3.1 days. Currently, 3.9% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

HOWL has been the subject of a number of research reports. Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Bank of America lowered their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Citizens Jmp cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright reduced their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics currently has an average rating of “Hold” and a consensus price target of $3.75.

Insider Activity at Werewolf Therapeutics

In related news, major shareholder Ansbert Gadicke sold 140,488 shares of the company’s stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total value of $171,395.36. Following the completion of the transaction, the insider owned 6,007,122 shares of the company’s stock, valued at approximately $7,328,688.84. This represents a 2.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of the stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total value of $171,395.36. Following the completion of the sale, the insider owned 6,007,122 shares of the company’s stock, valued at $7,328,688.84. The trade was a 2.29% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 5,628,304 shares of company stock worth $6,294,191. 23.60% of the stock is owned by corporate insiders.

Institutional Trading of Werewolf Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP raised its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares in the last quarter. Citadel Advisors LLC bought a new stake in Werewolf Therapeutics during the 3rd quarter valued at $304,000. Vanguard Group Inc. increased its holdings in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares during the period. Bridgeway Capital Management LLC raised its position in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Stock Performance

Shares of HOWL traded down $0.01 during midday trading on Tuesday, hitting $0.61. The stock had a trading volume of 621,893 shares, compared to its average volume of 906,133. The stock’s 50 day moving average is $1.06 and its 200 day moving average is $1.29. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics has a 1 year low of $0.56 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. Research analysts anticipate that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.